Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ)
· seekingalpha.com
Vir hepatitis delta combo hit its phase 3 goal, with phase 2 showing lasting viral suppression.
Vir plans to seek FDA approval in mid-2027 and expects additional Eclipse 2 and Eclipse 3 results in the first quarter of 2027. Breakthrough therapy and fast tr...